Advanced search
Publication Cover
Current Medical Research and Opinion Volume 32, 2016 - Issue 11
Submit an article Journal homepage
474
Views
13
CrossRef citations to date
0
Altmetric
Pulmonology

Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study

Urte SommerwerckDepartment of Pneumology, Ruhrlandklinik, West German Lung Centre, University Hospital Essen, Essen, Germany; ;Christiane Herzog Center Ruhr, Essen/Bochum, Germany;
,
Isabel Virella-LowellDepartment of Pediatrics, Medical University of South Carolina, Pediatric Pulmonology and Sleep Medicine, Charleston, SC, USA;
,
Gerhild AngyalosiNovartis Pharma AG, Basel, Switzerland;
,
Andrea ViegasNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Weihua CaoNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
&
Laurie DebonnettNovartis Pharmaceuticals Corporation, East Hanover, NJ, USACorrespondence[email protected]
Pages 1789-1795 | Received 30 Jul 2015, Accepted 05 Jul 2016, Published online: 09 Sep 2016

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Prakash Khadka, Jack Dummer, Philip C. Hill & Shyamal C. Das. (2024) The quest to deliver high-dose rifampicin: can the inhaled approach help?. Expert Opinion on Drug Delivery 21:1, pages 31-44.
Read now
Stanley B. Fiel & Erica A. Roesch. (2022) The use of tobramycin for Pseudomonas aeruginosa: a review. Expert Review of Respiratory Medicine 16:5, pages 503-509.
Read now
Arcadia Woods & Khondaker Miraz Rahman. (2018) Antimicrobial Molecules in the Lung: Formulation Challenges and Future Directions for Innovation. Future Medicinal Chemistry 10:5, pages 575-604.
Read now

Articles from other publishers (10)

David de la Rosa-Carrillo, Guillermo Suárez-Cuartín, Oriol Sibila, Rafael Golpe, Rosa-María Girón & Miguel-Ángel Martínez-García. (2023) Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review. Journal of Clinical Medicine 12:10, pages 3577.
Crossref
Carsten Schwarz, Giovanni Taccetti, Pierre-Regis Burgel & Siobhain Mulrennan. (2022) Tobramycin safety and efficacy review article. Respiratory Medicine 195, pages 106778.
Crossref
Sawittree Sahakijpijarn, Moeezullah Beg, Stephanie M. Levine, Jay I. Peters & Robert O. WilliamsIIIIII. (2021) A Safety and Tolerability Study of Thin Film Freeze-Dried Tacrolimus for Local Pulmonary Drug Delivery in Human Subjects. Pharmaceutics 13:5, pages 717.
Crossref
Rachel Yoon Kyung Chang, Philip Chi Lip Kwok, Sussan Ghassabian, John D. Brannan, Heikki O. Koskela & Hak‐Kim Chan. (2020) Cough as an adverse effect on inhalation pharmaceutical products. British Journal of Pharmacology 177:18, pages 4096-4112.
Crossref
Luis Máiz Carro & Marina Blanco-Aparicio. (2020) Nuevos antibióticos inhalados y formas de administración. Open Respiratory Archives 2:3, pages 251-264.
Crossref
Sawittree Sahakijpijarn, Hugh D.C. Smyth, Danforth P. Miller & Jeffry G. Weers. (2020) Post-inhalation cough with therapeutic aerosols: Formulation considerations. Advanced Drug Delivery Reviews 165-166, pages 127-141.
Crossref
Srilekha Panguluri, Praveen Gunda, Laurie Debonnett & Kamal Hamed. (2017) Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis. Clinical Drug Investigation 37:8, pages 795-805.
Crossref
Diego Maselli, Holly Keyt & Marcos Restrepo. (2017) Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. International Journal of Molecular Sciences 18:5, pages 1062.
Crossref
Kamal Hamed & Laurie Debonnett. (2017) Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence . Therapeutic Advances in Respiratory Disease 11:5, pages 193-209.
Crossref
Emily C. Tucker, Matthew B. Roberts & David L. Gordon. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 229 243 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.